PCLAF and myocardial infarction: Studies have shown that CHD and myocardial infarction in patients with endothelium and other factors due to long-term ischemia, hypoxia and endothelium chronic injury, the release of platelet activating factor (PAF) and other inflammatory substances, to decrease the release of 6-keto-PGF1α (Qinhua Chen, 2013).